http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Acerus Reports First Quarter 2017 Financial Results
-
Acerus to Report First Quarter 2017 Financial Results and Host Investor Call
-
Acerus Announces Appointment of Ken Yoon as Chief Financial Officer
-
Acerus to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
-
Acerus Announces NATESTO® Regulatory Filing in South Korea
-
Acerus Reports Fourth Quarter and Full Year 2016 Financial Results
-
Acerus Files a New Drug Submission for GYNOFLOR™ in Canada
-
Acerus to Report 2016 Financial Results and Host Investor Call
-
Acerus Announces NATESTO® Posters to Be Presented at the Endocrine Society 2017 Annual Meeting
-
ACERUS ANNOUNCES NATESTO® ABSTRACTS TO BE PRESENTED AT THE AMERICAN UROLOGICAL ASSOCIATION’S ANNUAL MEETING
-
Acerus Announces Completion of Loan Repayment
-
Acerus Comments on Decision Regarding Litigation
-
Acerus Announces NATESTO® License Agreement with Hyundai Pharm
-
Acerus Reports Third Quarter 2016 Financial Results
-
Acerus Announces Appointment of Tricia Symmes as Chief Operating Officer
-
Acerus to Announce Third Quarter 2016 Financial Results on November 2, 2016
-
Acerus Announces Canadian Commercial Launch of NATESTOTM
-
Acerus Comments on Trading Activity
-
Acerus Reports Second Quarter 2016 Results
-
Acerus to Announce Second Quarter 2016 Results on August 9, 2016
-
Acerus Appoints Mr. Luc Mainville to Its Board of Directors
-
Acerus Completes NATESTO® U.S. Transition
-
Acerus Announces Voting Results for the 2016 Annual General Meeting
-
Acerus Announces NATESTO™ Scientific Abstract Presentation at the 71St Annual Canadian Urological Association Meeting
-
Acerus Provides Update on Litigation
-
Acerus Reports First Quarter 2016 Results and Provides Business Update
-
Acerus Completes Private Placement of Common Shares
-
Acerus to Announce First Quarter 2016 Financial and Operating Results on May 4, 2016
-
Acerus to Present at the 2016 Bloom Burton & Co. Healthcare Investor Conference
-
Acerus Announces U.S. License Agreement for NATESTO®
-
Acerus Acquires Canadian Rights to GYNOFLOR™
-
Acerus Comments on Statement of Claim
-
CORRECTING and REPLACING: Acerus Announces Departure of Dr. Michael Bumby
-
Acerus Comments on Trading Activity
-
Acerus Comments on Notice of Action
-
Acerus Reports Fourth Quarter and Full Year 2015 Financial Results
-
Acerus to Report 2015 Financial Results and Host Investor Call
-
Amer Strategic Inc Portfolio (ASP) Announces Health Canada Approval For NATESTO
-
Acerus Receives Health Canada Approval For NATESTO™
-
Acerus Announces NATESTO™ Publication in Prominent Andrology Journal
-
Acerus Pharmaceuticals Terminates U.S. NATESTO Deal with Endo (ENDP)
-
Acerus Announces Termination of NATESTO™ Agreement with Endo
-
Acerus Announces Changes to Board of Directors
-
Acerus Announces Amendment to Loan Agreement
-
Acerus Reports Approval of ESTRACE® Generic in Canada
-
Acerus Provides Business Update and Announces Third Quarter 2015 Financial Results
-
Acerus to Report Third Quarter 2015 Results and Host Investor Call

